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ABSTRACT 
International Journal of Exercise Science 14(2): 435-445, 2021. Caffeine improves short-to-moderate 
distance running performance, but the effect of caffeine on repeated sprints are equivocal. This research determined 
if caffeine improved exercise tolerance during repeated-sprint exercise. iCV is a running velocity that distinguishes 
intermittent running velocities (velocities ≤ iCV) that are sustainable from those resulting in a predictable time to 
exhaustion (velocities > iCV). Seven physically active men (age = 21.6 ± 1.5 years, body mass = 72.8 ± 5.1 kg, VO2max 
= 56.9 ± 9.8 mL/kg/min) ingested caffeine (5 mg/kg) or placebo (crossover design) 60 min prior to an intermittent 
critical velocity (iCV) test. The treadmill grade and velocity at VO2max (vVO2max) were used for iCV testing, and 
consisted of 3 bouts (10 sec running and 10 sec passive rest) at 130, 110 and 120% vVO2max. Each bout continued 
until volitional exhaustion and was separated by 20 min of passive rest. Total distance and duration were recorded 
to determine exercise tolerance using the iCV model. Caffeine ingestion increased running duration at 110% 
vVO2max (p = 0.02), but not at 120 (p = 0.93) and 130% vVO2max (p = 0.14). Caffeine did not improve iCV model 
parameters. A single dose of caffeine consumed 60 min before repeated-sprints can improve performance at 110% 
vVO2max, but not at higher velocities.  
 





Many team-sport athletes perform repeated maximal or near-maximal effort sprints 
interspersed with recovery over 1-4 h, known as repeated sprint exercise (RSE) (14). Resistance 
to fatigue during RSE is known as repeated-sprint ability (RSA) (14), and characterized by a 
reduction in velocity/power output from a series of short (< 10 sec) sprints with brief recovery 
intervals (> 30 sec) (7, 11). RSA provides evidence for the presence of fatigue, but it fails to define 
a threshold where fatigue increases during RSE (11). A well-known feature of steady-state high-
intensity exercise is the curvilinear relationship between running velocity and time to 
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exhaustion, termed critical velocity or critical speed (5). This has been modeled to RSE, and 
identifies a novel fatigue threshold known as the intermittent critical velocity (iCV) (12, 13). iCV 
is a running velocity that distinguishes intermittent running velocities (velocities ≤ iCV) that are 
sustainable from those resulting in a predictable time to exhaustion (velocities > iCV). iCV, 
therefore, represents the boundary of exercise tolerance during intermittent high-intensity 
running (12, 13). The iCV model also describes an intermittent anaerobic running capacity 
(iARC) and critical rest interval (CRI). The iARC represents a finite distance that can be achieved 
before the accumulation of metabolites associated with fatigue, while CRI is a theoretical rest 
period that will enable RSE to continue without the onset of fatigue (12, 13). These measures are 
determined from a series of maximal effort bouts interspersed with short rest intervals. This 
approach may have utility since athletes engage in similar intensity efforts during high-quality 
intermittent exercise training sessions (31). 
 
Caffeine is widely used by athletes before competition to improve endurance performance, 
muscular strength and power, and augment exercise training adaptations (8, 9, 15, 17, 34). Up to 
89% of competitive athletes consume caffeine, and trained participants report daily 
consumption > 300 mg day (8, 27). There are several mechanisms that may be responsible for 
caffeine’s ergogenic properties. As an adenosine-receptor antagonist, caffeine reduces 
perception of pain and exertion (15, 22). Caffeine has also been reported to augment blood flow 
and muscle oxygenation by activation of endothelial nitric oxide synthase (32, 38). In addition, 
caffeine improves muscle function by modifying K+ and Ca2+ kinetics (1, 23). The dose that has 
typically been tested on running performance is 3-10 mg/kg body mass consumed 60 min before 
the activity (9, 15, 27). While this dosing strategy appears to be effective when running for 20-45 
min, the benefits of caffeine may not extend to longer duration running events (9). This may be 
due to the pharmacokinetics of caffeine, i.e. peak plasma concentrations are achieved within 45 
min of oral ingestion, and the half-life is 3-4 h (19).  
 
A single dose of caffeine (300 mg) ingested by recreationally active males before iCV testing did 
not improve RSE (36). Limited by the study design, the caffeine supplement contained other 
compounds and this may have interfered with caffeine’s metabolism (24, 36). Therefore, it 
remains unknown if caffeine, alone, improves iCV model parameters. The objective of this 
research was to establish if a moderate dose of caffeine consumed 60 min before iCV testing 
improves RSE performance. Our hypothesis was that caffeine would extend running time at 





Seven physically active men volunteered for the study (Table 1). Participants completed a 
health-history questionnaire, and were disqualified from study participation if they had 
cardiovascular, pulmonary, muscular, or metabolic disease; acute or chronic muscle pain or 
injury; suffered from seizures; were not between 18-25 years old; had a pacemaker or other 
internal device; followed a specialized or restricted diet; had unexplained weight loss in the past 
6 months; or experienced adverse events after caffeine consumption. The Department of Defense 
Int J Exerc Sci 14(2): 435-445, 2021 
International Journal of Exercise Science                                                          http://www.intjexersci.com 
437 
Health-related behaviors survey was also used to verify that participants met aerobic physical 
activity guidelines (Table 1). All participants completed a self-reported 7 d caffeine recall to 
determine daily caffeine consumption (Table 1). On average, the participants in this study were 
regular caffeine consumers, but consumed less caffeine than described in trained participants (≥ 
300 mg/d) (26, 28). Dietary intake prior to iCV testing was reported with a 24-h dietary recall 
using the Automated Self-Administered 24-h Dietary Assessment Tool (ASA24) developed by 
the National Cancer Institute (Bethesda, MD). Total energy and macronutrient intake were not 
significantly different between the caffeine (total energy 3036 ± 753 kcal; carbohydrate 297 ± 84 
g; protein 143.0 ± 17.8 g; fat 143.0 ± 27.2 g) and placebo sessions (total energy 3217 ± 899 kcal, p 
= 0.51; carbohydrate 424 ± 104 g, p = 0.11; protein 154.4 ± 32.6, p = 0.54; fat 110.9 ± 18.7 g, p = 
0.18). Each participant was briefed on the procedures and risks associated with study 
participation before providing written informed consent. The study was approved by the 
Kansas State University Institutional Review Board (#9607).  
 



























21.6±1.5 179.7±6.8 72.8±5.1 22.5±0.9 14.0±2.2 56.9±9.8 98.3±95.4 283.8±124.9 124.0±116.3 
Data are presented as mean ± standard deviation. 
 
Protocol 
A double-blind, counterbalanced, crossover design was employed to determine the effects of 
acute caffeine supplementation on exercise tolerance during RSE using the iCV model. The 
design was chosen to minimize participant recruitment needs while achieving adequate 
statistical power. Eight participants were needed based on a large effect size of caffeine 
supplementation (0.8), at α = 0.05 with 80% power (39). Caffeine and placebo (biotin) pills were 
used based on recommendations from a registered dietitian, and a moderate dose of caffeine (5 
mg/kg body mass) was selected based on previous investigations (37). The iCV model was used 
to evaluate exercise tolerance during RSE because it is reliable and has been previously used in 
other ergogenic evaluations (13, 36). Participants visited the laboratory three times over two 
weeks. All testing was scheduled between 8:00 AM and 12:00 PM. Participants were encouraged 
to continue their normal exercise and dietary habits during the study. Participants were 
instructed to refrain from caffeine and alcohol for 12 h, and vigorous physical activity for 24 h 
before testing. Additionally, participants refrained from eating 2-3 h prior to VO2max testing.  
Participants were provided a standardized meal (Boost™ meal replacement shake) 3 h prior to 
each iCV test that comprised ~20% of their estimated total energy expenditure (18). Multiple 
servings of the meal replacement shake (kcal = 240, carbohydrate = 41 g, protein = 10 g, fat = 4 
g) were used to satisfy the estimated energy expenditure when necessary. A list of the meal 
replacement shake ingredients is provided in Supplement A. All procedures and measurements 
performed were compliant with the International Journal of Exercise Science guidelines (25).  
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Anthropometric Measurements: Height was measured using a stadiometer. Body mass, body mass 
index, basal metabolic rate, and percent fat were determined using bioelectrical impedance 
analysis in standard mode (TBF-300A; Tanita, Japan).  
 
VO2max protocol: On their first laboratory visit, participants performed a graded exercise test 
(GXT) to volitional exhaustion on a treadmill (Woodway Pro, Waukesha, WI) to determine 
VO2max and velocity at VO2max (vVO2max). The GXT consisted of two 3-min warm-up stages at 4-
and 5 km/h. Treadmill velocity was set to 6 – 10 km/h, based on participant’s reported level of 
fitness, and increased by 0.5 km/h every min until 95% of the predicted maximal heart rate (220-
age) was achieved. The velocity was then decreased by 1.0 km/h and the grade increased by 
1.0% every min until volitional exhaustion. VO2max was confirmed using a validation protocol 
after 15-20 min of passive recovery (29). Briefly, participants lowered themselves onto the 
treadmill set at the highest grade, and 110% of vVO2max achieved during the GXT. VO2 was 
recorded using open circuit spirometry (TrueOne 2400, Parvo-Medics, Waukesha, WI) and 
measured continuously throughout the GXT and the VO2max validation tests. The three highest 
15-s VO2 values were averaged and considered the VO2max values for the GXT and VO2max 
validation protocols. VO2max was considered valid if the VO2 obtained on the VO2max validation 
test was less than 0.2 L/min higher than that achieved during the GXT. All participants 
performed the validation test and achieved their VO2max. 
 
Supplementation protocol: Participants returned to the laboratory for the second visit after a 
minimum of 48 h. Participants consumed caffeine (5 mg/kg) or a biotin placebo (Solgar, 300 µg) 
60 min before testing. The placebo was indistinguishable from the caffeine pill. After ingesting 
the supplement and prior to warming-up for the iCV test, participants completed the dietary 
recall. Participants returned to the laboratory after at least a 7 d washout period to repeat 
exercise testing with the other supplement. 
 
iCV protocol: The iCV test protocol followed the same procedures used in the reliability study 
conducted by Fukuda and colleagues (13). In order to minimize learning effects and ensure 
safety, participants were familiarized with brief intermittent running bouts, and then completed 
a 5 min warm-up at a self-selected pace. The treadmill (Woodway Pro, Waukesha, WI) grade 
was set to the highest level obtained during the GXT for iCV testing. Participants completed 3 
sets at 130-, 110- and 120% vVO2max interspersed by 20 min of passive recovery, each to volitional 
fatigue. As specified by Fukuda and colleagues (13), the order of iCV test running bouts were 
not randomized across participants. Each set consisted of 10 sec of running followed by 10 sec 
of passive recovery. Water was available ad libitum during passive rest periods. Participants 
mounted and dismounted the treadmill (Woodway Pro, Waukesha, WI, USA) by lowering 
themselves onto the treadmill belt during running bouts and straddling the treadmill during 
passive rest.  
Participants repeated 10 sec running bouts during each set until they could no longer maintain 
the selected velocity or complete the full 10 sec running bout. The total duration (running + rest), 
running duration only, the number of running bouts (determined by lap counter), and total 
distance covered were determined for each set. The linear, total distance model (L-TD) (13) was 
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used to determine iCV and iARC with the following equation, where total distance was (time x 
velocity) and time was the exercise duration: 
 
𝑇𝑜𝑡𝑎𝑙	𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒	 = 𝑖𝐴𝑅𝐶 + 𝑖𝐶𝑉	𝑥	𝑡𝑖𝑚𝑒 
 
The iCV represents the slope of the regression line of exercise distance and duration, while iARC 
represents the y-intercept.  
 
CRI was determined with the following equation, where TD, ΣINT and iCVCRI represented the 
total distance of all sets, the total number of running bouts completed in all sets, and the slope 
of the linear regression between total distance and the total duration of the exercise bout 
(exercise + rest), respectively:  




The L-TD model was also used to establish an alternative iCV to determine the CRI (iCVCRI): 
 
𝑖𝐶𝑉!"# =
𝑇𝑜𝑡𝑎𝑙	𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒	(𝑚); 𝛴	(130%	 + 	110%	 + 	120%	𝑃𝑉)
𝑇𝑜𝑡𝑎𝑙	𝐷𝑢𝑟𝑎𝑡𝑖𝑜𝑛	[𝑒𝑥𝑒𝑟𝑐𝑖𝑠𝑒 + 𝑟𝑒𝑠𝑡](𝑠); 	𝛴	(130%	 + 	110%	 + 	120%	𝑃𝑉) 
 
RPE and Adverse Event Measurements: Participants reported their ratings of perceived exertion 
(RPE) using the 15-point Borg scale after each set (4). RPE was averaged for each iCV test. 
Participants completed a brief questionnaire immediately after the last exercise bout and 
indicated, “yes” or “no”, if they perceived an effect from the supplement that was provided. An 
online survey was used to determine if any adverse events occurred in the immediate hours 
after testing and the following day. Participants were asked to complete surveys prior to bed 
and upon awakening. 
 
Statistical Analysis 
Data were analyzed with SPSS version 25.0 (IBM, Armonk, NY, USA). The level of significance 
was set at α = 0.05. Three volunteers did not complete the study due to scheduling conflicts (n = 
1) or failure to follow-up after testing (n = 2), leaving a final sample of seven participants. 
Normality was determined using a Kolmogorov-Smirnov test. Exercise duration (110, 120, and 
130% of vVO2max), RPE, iCV, iARC, and CRI were normally distributed and analyzed using a 
paired t-test, and reported as means ± SD and 95% CI. iCV and iARC display the highest 
reliability (ICC = 0.89, SEM = 0.2 m/s, CV = 12.4-15.4%; ICC = 0.80, SEM = 28.6 m, CV = 45.2-
49.9%) and CRI displays moderate reliability (ICC = 0.59, SEM = 1.5 s, CV = 8.2-10.7%) (13). 
Hedge’s g was used to indicate effect size (ES) and was classified as “trivial” (< 0.19), “small” 
(0.20-0.49), “moderate” (0.50-0.79), and “large” (> 0.80) (10). Adverse events measures were 
reported as percentage of individuals reporting an event in each condition. 
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Participant characteristics are shown in Table 1. Of the running velocities tested, caffeine 
extended mean running time by 99 sec at 110 vVO2max (placebo 294 ± 29 sec, 95%CI [267, 322]; 
caffeine 393 ± 95 sec, 95%CI [304, 481]; p = 0.020, g = 1.4) (Figure 1). While there were no 
significant differences between placebo and caffeine at 120% (placebo 229 ± 84 sec, 95%CI [151, 
306]; caffeine 231 ± 33.4 sec, 95%CI [201, 262]; p = 0.93, g = 0.045) or 130% vVO2max (placebo 160 
± 10 sec, 95%CI [135, 185]; caffeine 191 ± 46 sec, 95%CI [149, 234]; p = 0.14, g = 0.83), 6 of the 7 
participants increased their running duration at 130% vVO2max.  
 
 
Figure 1. Differences in exercise duration during the iCV test between placebo and caffeine conditions (N = 7). (A) 
Exercise duration during 110% of PV bout. (B) Exercise duration during 120% of PV bout. (C) Exercise duration 
during 130% of PV bout. Data are presented as means ± SD. * Denotes significant differences (p < 0.05) between the 
caffeine and placebo condition. 
 
Figure 2 illustrates iCV, iARC, CRI or RPE between conditions. iCV was not significant different 
between the caffeine (3.11 ± 1.1 m/s, 95%CI [2.1, 4.1]) and placebo condition (3.02 ± 0.97, 95%CI 
[2.1, 3.9], p = 0.81, g = 0.08). iARC was not significantly different between the caffeine (280.0 ± 
132.1 m, 95%CI [157.8, 402]) and placebo condition (256.1 ± 115.2 m, 95%CI [149.5, 362.6], p = 
0.63, g = 0.180). CRI was not significantly different between the caffeine (29.4 ± 11.4 s, 95%CI 
[18.8, 40.0]) and placebo condition (29.3 ± 7.4 s, 95%CI [22.5, 36.1], p = 0.97, g = 0.009). RPE was 
not significantly different between the caffeine (18.3 ± 1.5, 95%CI [16.9, 19.7]) and the placebo 
condition (18.6 ± 1.3, 95%CI [17.4, 19.8], p = 0.16, g = 0.20). Participants reported a perceived 
effect of the supplement (85.7% vs. 28.6%), increased activeness (42.9% vs. 14.3%) and 
gastrointestinal problems (28.2% vs. 0%) with caffeine compared to placebo. Additionally, one 
participant reported indigestion (14.3%) after consuming the placebo.  
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Figure 2. iCV parameters and ratings of perceived exertion between placebo and caffeine conditions (N = 7). (A) 
Intermittent critical velocity. (B) Intermittent Anaerobic Running Capacity. (C) Critical rest interval. (D) Ratings of 




The purpose of our investigation was to determine the effect of acute caffeine supplementation 
on exercise tolerance during RSE in physically active males utilizing the iCV model. The ability 
to resist fatigue during RSE is a key attribute to many sporting disciplines, where athletes are 
reported to use ergogenic aids (8, 14). Improvements in iCV and CRI reflect resilience to fatigue 
and rapid recovery during RSE, respectively (12). In this study, we determined that ingesting 5 
mg/kg of caffeine 60 min before iCV testing increased running duration at 110% vVO2max , but 
not at 120- or 130%, or in any parameter of exercise tolerance, or RPE during RSE. 
 
Our findings, similar to other reports, suggest that caffeine supplementation may improve some, 
but not all sprints during RSE (4, 8, 22, 23). Extending the duration of high-intensity running, 
increases the distance covered by an athlete. Interestingly, Del Coso et al. (2012) reported that 
caffeine improved the distance covered at the end of the first half of a simulated soccer match, 
and at some running intensities but not all. Our investigation found that caffeine improved the 
second set of sprints; thus, caffeine may improve RSE in a time and intensity dependent manner. 
The utility of improving the exercise tolerance at 110% of vVO2max may have implications for 
middle distance athletes since 110%vVO2max is a similar running velocity attained during high-
intensity intermittent training sessions (31).  
 
In the previous study by Spradley and colleagues (36), the highest running velocity used during 
iCV testing was at 110% of vVO2max, yet they did not find an ergogenic effect like we did at the 
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same velocity. Caffeine extends exercise duration between 75-85% of vVO2max during 
continuous exercise; however, it is unknown if caffeine improved RSE at exercise intensities 
below 110% of vVO2max (9). The investigation by Spradley and colleagues (2012) reported that a 
multi-ingredient pre-workout supplement containing an absolute dose of 300 mg of caffeine (< 
4 mg/kg of body weight) did not improve iCV or iARC. It is possible that the dose of caffeine 
used by Spradley and the current investigation was insufficient to cause an increase in exercise 
tolerance to RSE. Investigators have reported that ergogenic doses of caffeine range from 3-10 
mg/kg body mass (9, 15, 28), but for RSA a dose found to be ergogenic was 6 mg/kg body mass 
(20, 21). Thus, higher doses of caffeine may be necessary to offset the perturbations to the muscle 
milieu during RSE by increasing calcium release from the sarcoplasmic reticulum and retaining 
potassium ions (1, 14, 23). 
 
Moderate-doses of caffeine act on multiple target tissues to antagonize adenosine receptors (A1 
and A2A receptors), which decrease RPE (22). Our study found no significant difference in RPE 
after acute caffeine supplementation, similar to other reports (2, 37). In some investigations, 
caffeine results in an increase in performance with no changes in RPE (2, 35). This suggests that 
caffeine is ergogenic by maintaining RPE at higher workloads, which is reported to enhance 
exercise training adaptations when caffeine-containing products are consumed prior to training 
sessions (34). 
 
The current investigation employed a study design with participants serving as their own 
controls, provided standardized meals prior to iCV testing, and was the first study to determine 
the effects of acute caffeine supplementation on exercise tolerance during RSE using the iCV 
model; all of which, contributed to the study’s strengths. However, by only recruiting young, 
physically active men, our results cannot be generalized to women, middle-age adults, or 
participants with lower physical activity levels. Caffeine metabolism is prolonged by estrogen 
and oral contraceptives, however, improvements in performance have been reported to be 
similar between sexes (35). Additionally, a large effect size was used to determine sample size 
and a larger number of participants would have allowed for the determination of a small effect 
during RSE. By failing to recruit enough participants to achieve adequate statistical power, these 
findings may be prone to increased type 2 error (i.e., false negative) and merits further 
investigation.  
 
Although our study lacked invasive measures to determine plasma caffeine concentration and 
caffeine metabolism, the likelihood that caffeine supplementation from caffeinated pills 
increases plasma caffeine concentration has substantial support given that it is used as a 
standard when comparing caffeinated products (19). Interestingly, caffeine is likely ergogenic 
in the absence of elevated plasma caffeine concentrations, as suggested by caffeine’s ergogenic 
properties when mouth rinsing caffeinated fluids (3). However, caffeine may not be ergogenic 
for all athletes, which may be in part associated with genetic influences from the CYP1A2 and 
ADORA2A polymorphisms (30, 40). The CYP1A2 gene encodes cytochrome P450 1A2, an 
enzyme responsible for 95% of caffeine metabolism and determines the pharmacokinetic 
response of caffeine metabolism (16). Carriers of the C allele (slow metabolizers) in the CYP1A2 
gene have been characterized as “non-responders” after caffeine supplementation, although 
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these findings are preliminary with conflicting reports (16, 30). We were not able to characterize 
the genetic differences among our participants, which presents an avenue for future research.  
 
Almost 90% of participants indicated a perceived effect from the supplement during the caffeine 
condition which may indicate poor blinding to the treatment conditions. Despite reports of 
increased effect from participants correctly identifying a supplement with an active ingredient, 
we failed to confirm these findings via their RSE performance (33). Lastly, while our iCV 
protocol replicated Fukuda and colleagues (13), the authors did not provide rationale for the 
130%, 110%, and 120% PV testing order; results may differ if the running set intensities were 
randomized between participants. 
 
RSA is a key attribute among many team sport athletes and remains a priority for strength and 
conditioning specialists and coaches. Our findings suggest that an acute dose of caffeine 
provides significant improvements in tolerance to RSE in physically active men at 110% of 
vVO2max, but not at higher velocities, nor did caffeine have any effect on RPE. Our RSA protocol 
utilized exhaustive RSE, which may replicate prolonged gameplay (i.e., overtime) or some high-
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Supplement A - Meal replacement shake ingredients 
Water, Glucose Syrup, Sugar, Milk Protein Concentrate, And Less Than 2% Of Vegetable Oil 
(Canola, High Oleic Sunflower, Corn) Vitamins And Minerals‡, Soy Protein Isolate, Gum 
Acacia, Fructooligosaccharides, Inulin (From Chicory), Cellulose Gel And Gum, Salt, Soy 
Lecithin, Natural And Artificial Flavor, Carrageenan, Stevia Leaf Extract 
 
‡Vitamins And Minerals: Magnesium Phosphate, Potassium Citrate, Potassium Chloride, 
Calcium Carbonate, Sodium Ascorbate, Choline Bitartrate, Calcium Phosphate, Ferrous Sulfate, 
Dl-Alpha Tocopheryl Acetate, Zinc Sulfate, Niacinamide, Calcium Pantothenate, Manganese 
Sulfate, Pyridoxine Hydrochloride, Riboflavin, Thiamine Hydrochloride, Vitamin A Palmitate, 
Copper Sulfate, Folic Acid, Potassium Iodide, Vitamin K1, Chromium Chloride, Sodium 
Selenite, Biotin, Sodium Molybdate, Vitamin D3, Vitamin B12 
 
 
 
 
